Cargando…

Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study

PURPOSE: To assess the long-term morpho-functional retinal and choroidal changes in chronic central serous chorioretinopathy (cCSC) pachychoroid eyes in response to continuous oral eplerenone (EPL) treatment. METHODS: This pilot study was conducted on patients with unilateral exudative cCSC. We enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Boscia, Giacomo, Viggiano, Pasquale, Marzulli, Federica, Grassi, Maria Oliva, Puzo, Pasquale, Dore, Stefano, Pinna, Antonio, Alessio, Giovanni, Boscia, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361091/
https://www.ncbi.nlm.nih.gov/pubmed/37483844
http://dx.doi.org/10.2147/OPTH.S411094
_version_ 1785076156351905792
author Boscia, Giacomo
Viggiano, Pasquale
Marzulli, Federica
Grassi, Maria Oliva
Puzo, Pasquale
Dore, Stefano
Pinna, Antonio
Alessio, Giovanni
Boscia, Francesco
author_facet Boscia, Giacomo
Viggiano, Pasquale
Marzulli, Federica
Grassi, Maria Oliva
Puzo, Pasquale
Dore, Stefano
Pinna, Antonio
Alessio, Giovanni
Boscia, Francesco
author_sort Boscia, Giacomo
collection PubMed
description PURPOSE: To assess the long-term morpho-functional retinal and choroidal changes in chronic central serous chorioretinopathy (cCSC) pachychoroid eyes in response to continuous oral eplerenone (EPL) treatment. METHODS: This pilot study was conducted on patients with unilateral exudative cCSC. We enrolled a total of 17 exudative cCSC and 17 non-exudative fellow eyes of 17 patients. Baseline best-corrected visual acuity (BCVA) and anatomical (structural optical coherence tomography [OCT] and OCT angiography) parameters in both eyes were collected at baseline. Follow-up data were collected at 6, 12, and 48 months after initiation of EPL treatment. RESULTS: (i) Exudative cCSC eyes: Compared with baseline (0.34±0.13 LogMAR), BCVA significantly improved at follow-up examinations (6 months: 0.28±0.13 LogMAR, p=0.039; 12 months: 0.22±0.11 LogMAR, p=0.025; 48 months: 0.21±0.08 LogMAR, p=0.028). Furthermore, there was a significant reduction from baseline in all structural OCT parameters (subretinal fluid and subfoveal choroidal thickness [SFCT]; p<0.05). (ii) Non-exudative fellow eyes: There was no significant change in BCVA. There was a significant reduction from baseline in SFCT and choriocapillaris flow deficit percentage (p<0.05). CONCLUSION: In this pilot study, continuous oral EPL therapy in cCSC pachychoroid eyes resulted in long-term morpho-functional improvement. The beneficial effect of EPL occurred within the first year and was maintained after four years. Based on these preliminary observations, EPL may be effective in the exudative forms of CSC.
format Online
Article
Text
id pubmed-10361091
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103610912023-07-22 Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study Boscia, Giacomo Viggiano, Pasquale Marzulli, Federica Grassi, Maria Oliva Puzo, Pasquale Dore, Stefano Pinna, Antonio Alessio, Giovanni Boscia, Francesco Clin Ophthalmol Original Research PURPOSE: To assess the long-term morpho-functional retinal and choroidal changes in chronic central serous chorioretinopathy (cCSC) pachychoroid eyes in response to continuous oral eplerenone (EPL) treatment. METHODS: This pilot study was conducted on patients with unilateral exudative cCSC. We enrolled a total of 17 exudative cCSC and 17 non-exudative fellow eyes of 17 patients. Baseline best-corrected visual acuity (BCVA) and anatomical (structural optical coherence tomography [OCT] and OCT angiography) parameters in both eyes were collected at baseline. Follow-up data were collected at 6, 12, and 48 months after initiation of EPL treatment. RESULTS: (i) Exudative cCSC eyes: Compared with baseline (0.34±0.13 LogMAR), BCVA significantly improved at follow-up examinations (6 months: 0.28±0.13 LogMAR, p=0.039; 12 months: 0.22±0.11 LogMAR, p=0.025; 48 months: 0.21±0.08 LogMAR, p=0.028). Furthermore, there was a significant reduction from baseline in all structural OCT parameters (subretinal fluid and subfoveal choroidal thickness [SFCT]; p<0.05). (ii) Non-exudative fellow eyes: There was no significant change in BCVA. There was a significant reduction from baseline in SFCT and choriocapillaris flow deficit percentage (p<0.05). CONCLUSION: In this pilot study, continuous oral EPL therapy in cCSC pachychoroid eyes resulted in long-term morpho-functional improvement. The beneficial effect of EPL occurred within the first year and was maintained after four years. Based on these preliminary observations, EPL may be effective in the exudative forms of CSC. Dove 2023-07-17 /pmc/articles/PMC10361091/ /pubmed/37483844 http://dx.doi.org/10.2147/OPTH.S411094 Text en © 2023 Boscia et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Boscia, Giacomo
Viggiano, Pasquale
Marzulli, Federica
Grassi, Maria Oliva
Puzo, Pasquale
Dore, Stefano
Pinna, Antonio
Alessio, Giovanni
Boscia, Francesco
Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title_full Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title_fullStr Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title_full_unstemmed Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title_short Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study
title_sort continuous eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361091/
https://www.ncbi.nlm.nih.gov/pubmed/37483844
http://dx.doi.org/10.2147/OPTH.S411094
work_keys_str_mv AT bosciagiacomo continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT viggianopasquale continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT marzullifederica continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT grassimariaoliva continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT puzopasquale continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT dorestefano continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT pinnaantonio continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT alessiogiovanni continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy
AT bosciafrancesco continuouseplerenonetreatmentinchroniccentralserouschorioretinopathylongtermresultsfromapilotstudy